Literature DB >> 2225316

The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats.

K S Hall1, L Endresen, L Schjerven, H E Rugstad.   

Abstract

Preoperative administration of 4'-epidoxorubicin (Epi-A) has been suggested as adjuvant therapy in patients undergoing liver resection for hepatocarcinoma. To assess the influence of partial hepatectomy on the pharmacokinetics of Epi-A, an experimental study in rats was undertaken in which 5 mg/kg Epi-A was given i.v. 10 min prior to a 2/3 hepatic resection or sham operation. Epi-A levels in liver tissue and plasma were determined using a sensitive and specific HPLC method. A marked uptake of Epi-A in liver tissue was found at 10 min after injection. The partially hepatectomized rats showed a 2-fold increase in AUC between 4 and 72 h as compared with the sham-operated controls. The terminal half-life from 24 to 72 h was not significantly changed by the partial hepatectomy. The plasma binding of Epi-A was measured at 4 h post-surgery. The fraction of unbound Epi-A was 0.16 in partially hepatectomized animals and 0.20 in sham-operated rats. The results indicate that when Epi-A is given prior to liver resection, a dose reduction might be necessary to avoid increased side effects due to the rise in AUC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225316     DOI: 10.1007/bf02994096

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Liver circulation and function.

Authors:  R W BRAUER
Journal:  Physiol Rev       Date:  1963-01       Impact factor: 37.312

2.  Demonstration of liver regeneration by splenoportal venography.

Authors:  A H ISLAMI; G T PACK
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1959-05

3.  A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.

Authors:  C P Holton; J D Burrington; E I Hatch
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

4.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

5.  High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue.

Authors:  L M Rose; K F Tillery; S M el Dareer; D L Hill
Journal:  J Chromatogr       Date:  1988-03-18

Review 6.  Survival after liver resection for cancer.

Authors:  J H Foster
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

7.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.

Authors:  S Eksborg; H Ehrsson; I Andersson
Journal:  J Chromatogr       Date:  1979-12-01

8.  Protein binding of anthraquinone glycosides, with special reference to adriamycin.

Authors:  S Eksborg; H Ehrsson; B Ekqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

Authors:  K Mross; P Maessen; W J van der Vijgh; H Gall; E Boven; H M Pinedo
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

10.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

View more
  2 in total

1.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

2.  Influence of partial hepatectomy in rats on the activity of hepatic microsomal enzymatic systems.

Authors:  A M Maza; A R Gascon; M B Calvo; R M Hernandez; M A Monte; J J Marin; A Dominguez-Gil; J L Pedraz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.